97-18459. Oral Dosage Form New Animal Drugs; Pyrantel Pamoate Suspension  

  • [Federal Register Volume 62, Number 135 (Tuesday, July 15, 1997)]
    [Rules and Regulations]
    [Pages 37711-37712]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-18459]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 520
    
    
    Oral Dosage Form New Animal Drugs; Pyrantel Pamoate Suspension
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of a supplemental abbreviated new 
    animal drug application (ANADA) filed by Lambert-Kay, Division of 
    Carter-Wallace, Inc. The supplemental ANADA provides for oral use 4.54 
    milligrams per milliliter (mg/mL) pyrantel pamoate suspension in 
    addition to the 2.27 mg/mL product for removal of large roundworms and 
    hookworms in puppies and dogs and to prevent reinfections of Toxocara 
    canis in puppies and adult dogs and in lactating bitches after 
    whelping.
    
    EFFECTIVE DATE: July 15, 1997.
    
    FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for 
    Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-1623.
    
    SUPPLEMENTARY INFORMATION: Lambert-Kay, Division of Carter-Wallace, 
    Inc., P.O. Box 1001, Half Acre Rd., Cranbury, NJ 08512-0181, filed a 
    supplement to ANADA 200-028 that provides for oral use of 4.54 mg/mL of 
    Evict, Lassie, and Vet's Own (pyrantel 
    pamoate) liquid wormer for removal of large roundworms (T. canis and 
    Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria 
    stenocephala) in puppies and dogs and to prevent reinfections of T. 
    canis in puppies and adult dogs and in lactating bitches after 
    whelping. The supplemental ANADA provides for use of 4.54 mg/mL 
    pyrantel pamoate suspension in addition to 2.27 mg/mL suspension.
        Approval of supplemental ANADA 200-028 for Lambert-Kay's pyrantel
    
    [[Page 37712]]
    
    pamoate suspension is as a generic copy of Pfizer's NADA 100-237 Nemex-
    2TM (pyrantel pamoate) suspension. The supplemental ANADA is 
    approved as of June 4, 1997, and the regulations are amended in 21 CFR 
    520.2043(b)(2) to reflect the approval. The basis of approval is 
    discussed in the freedom of information summary.
        In accordance with the freedom of information provisions of 21 CFR 
    part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
    data and information submitted to support approval of this application 
    may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
    Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, 
    between 9 a.m. and 4 p.m., Monday through Friday.
        The agency has determined under 21 CFR 25.24(d)(1)(i) that this 
    action is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
    List of Subjects in 21 CFR Part 520
    
        Animal drugs.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
    amended as follows:
    
    PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
    
        1. The authority citation for 21 CFR part 520 continues to read as 
    follows:
    
        Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act 
    (21 U.S.C. 360b).
    
        2. Section 520.2043 is amended by revising paragraph (b)(2) to read 
    as follows:
    
    Sec. 520.2043  Pyrantel pamoate suspension.
    
    * * * * *
        (b) * * *
        (2) Sponsors. See Nos. 000069 and 011615 for use of 2.27 and 4.54 
    milligrams per milliliter product. See No. 023851 for use of 4.54 
    milligrams per milliliter product.
    * * * * *
    
        Dated: June 20, 1997.
    Robert C. Livingston,
    Director, Office of New Animal Drug Evaluation, Center for Veterinary 
    Medicine.
    [FR Doc. 97-18459 Filed 7-14-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Effective Date:
7/15/1997
Published:
07/15/1997
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
97-18459
Dates:
July 15, 1997.
Pages:
37711-37712 (2 pages)
PDF File:
97-18459.pdf
CFR: (1)
21 CFR 520.2043